Recursion Pharmaceuticals, Inc. (RXRX) Institutional Ownership

Ownership Summary

The institutional landscape for Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) includes 318 filers as of the latest reporting cycle ending September 2025.

• Institutional ownership in Recursion Pharmaceuticals edged down to 75.0% in September 2025, compared to 76.4% in June 2025.
• Institutional share ownership changed by 6.18% QoQ, while the number of institutional owners saw an increase of 20.00% YoY.
• Among the 318 institutional holders of Recursion Pharmaceuticals, 162 added to their stakes while 89 trimmed their positions and 67 held steady.
• The aggregate institutional position in Recursion Pharmaceuticals now stands at 325.76Mn shares as of September 2025, after investors increased their holdings (up by 18.97Mn shares quarter on quarter which is up 62.13Mn shares year over year).
• As of September 30, 2025, VANGUARD GROUP INC held Recursion Pharmaceuticals's largest shareholding position with over 39.78Mn shares, representing 9.16% of total outstanding shares.
• Among the most significant buyers of Recursion Pharmaceuticals during September 2025 were STATE STREET CORP (7.09Mn), VANGUARD GROUP INC (3.71Mn), BlackRock, Inc. (3.37Mn), SUSQUEHANNA INTERNATIONAL GROUP, LLP (2.18Mn), GEODE CAPITAL MANAGEMENT, LLC (1.85Mn).
• Leading sellers of Recursion Pharmaceuticals stock in September 2025 included FMR LLC (2.36Mn), Novo Holdings A/S (1.74Mn), Caption Management, LLC (1.51Mn), CITADEL ADVISORS LLC (1.31Mn), UBS Group AG (876.81K).
• The top 10 institutional holders of Recursion Pharmaceuticals for the quarter ending September 2025 included VANGUARD GROUP INC (39.78Mn), ARK Investment Management LLC (33.55Mn), BlackRock, Inc. (31.74Mn), BAILLIE GIFFORD & CO (23.98Mn), STATE STREET CORP (18.27Mn), SOFTBANK GROUP CORP. (14.67Mn), Kinnevik AB (publ) (13.43Mn), Mubadala Investment Co PJSC (12.99Mn), MIC Capital Management UK LLP (9.64Mn), GEODE CAPITAL MANAGEMENT, LLC (9.62Mn).